Disease: Hyperkeratosis ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0870082
Disease: Hyperkeratosis
Hyperkeratosis 		0.130 Biomarker disease BEFREE Our analysis of data has demonstrated that combined BRAF and MEK inhibitor-based treatment is associated with an increased risk of all-grade rash and a decreased risk of all-grade and high-grade HK, SP, alopecia, cSCC, HFS, and PR compared with single BRAF inhibitor alone in melanoma patients. 30501438 2019
CUI: C0870082
Disease: Hyperkeratosis
Hyperkeratosis 		0.130 Biomarker disease BEFREE Vemurafenib is a selected BRAF kinase inhibitor approved for treating metastatic or unresectable melanoma, which has numerous cutaneous side effects unfortunately, including three previously reported cases of asymptomatic areola and/or nipple hyperkeratosis. 28211633 2017
CUI: C0870082
Disease: Hyperkeratosis
Hyperkeratosis 		0.130 GeneticVariation disease BEFREE Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors. 22726224 2012
CUI: C0870082
Disease: Hyperkeratosis
Hyperkeratosis 		0.130 Biomarker disease HPO